Get to know our clinical trials

Trial to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of AZD0022 in monotherapy and in combination with antineoplastic agents in patients with tumors carrying a KRASG12D mutation (ALAFOSS-01).

THE OBJECTIVE OF THE RESEARCH TRIAL IS TO OBTAIN MORE INFORMATION ABOUT AZD0022 AND ALSO TO BETTER UNDERSTAND THE DISEASE BEING STUDIED AND THE ASSOCIATED HEALTH PROBLEMS.

Imagen del Dr. Mariano Ponz -Sarvisé, especialista en Oncología Médica de la Clínica Universidad de Navarra. El Dr. Ponz-Sarvisé se dedica preferencialmente a los tumores de páncreas y vías biliares.
Dr. Mariano Ponz-Sarvisé Curriculum
Specialist Medical Oncology Department
Navarre headquarters
Cancer Center
Liver and Pancreatic Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • PHASE I/IIA, OPEN-LABEL, MULTICENTER SCREENING, OPTIMIZATION AND DOSE EXPANSION TRIAL TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF AZD0022 IN MONOTHERAPY AND IN COMBINATION WITH ANTINEOPLASTIC AGENTS IN PATIENTS WITH TUMORS CARRYING A KRASG12D MUTATION (ALAFOSS-01).
  • Code EudraCT: 2024-516699-14-00
  • Protocol number: D7080C00001
  • Promoter: AstraZeneca Farmacéutica Spain
  • Molecule/Drug: AZD0022

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION